mGluR3/GRM3 recombinant proteins and antibodies

Metabotropic glutamate receptor 3 (mGluR3), encoded by GRM3 (also known as GPRC1C or MGLUR3) gene, is a member of the metabotropic glutamate receptor family and a G protein-coupled receptor (GPCR). mGluR3 plays a critical role in the brain and central nervous system (CNS), particularly in regulating neurotransmitter release, synaptic transmission, and brain plasticity. By binding with neurotransmitters like glutamate, mGluR3 is involved in key neurobiological processes, including learning, memory, emotion, and mental state regulation.

In neuroscience, mGluR3 is considered a promising target for treating neuropsychiatric and neurodegenerative diseases. Studies have shown that dysfunction of mGluR3 is closely associated with several psychiatric disorders, such as schizophrenia, depression, autism spectrum disorder (ASD), and Alzheimer’s disease (AD). Abnormal expression or dysfunction of mGluR3 is believed to contribute to the pathogenesis of these diseases. Activation of mGluR3 can improve synaptic transmission between neurons, repair neural networks, and potentially alleviate symptoms associated with these conditions.

Current drug development targeting mGluR3 is mainly focused on small molecule agonists and antagonists. mGluR3 agonists aim to activate the receptor, improving neurotransmission and enhancing synaptic plasticity, thereby potentially treating psychiatric and neurodegenerative disorders. On the other hand, mGluR3 antagonists are primarily being developed to inhibit excessive activation of mGluR3, alleviating the neuropsychological symptoms caused by its overactivation, particularly in conditions like schizophrenia.

Several biopharmaceutical companies are actively involved in the development of drugs targeting mGluR3. Axovant Gene Therapies in the United States is developing an mGluR3 agonist, aiming to enhance the receptor’s function for treating Alzheimer’s disease and other neurodegenerative conditions. Additionally, pharmaceutical giants like Pfizer and Novartis are also conducting research on mGluR3-targeted drugs. Pfizer is investigating an mGluR3 agonist for the treatment of depression and autism spectrum disorder (ASD), while Novartis is developing an mGluR3 antagonist to improve cognitive function in schizophrenia patients. As research into mGluR3 receptors progresses, it is expected that more innovative drugs will enter clinical trials, especially for neuropsychiatric and neurodegenerative diseases. mGluR3 will likely become a key drug target, offering patients more treatment options and improving their quality of life in the future.

To assist in the development of drugs targeting mGluR3, DIMA BIOTECH can now provide full-length mGluR3 recombinant membrane protein developed by its nanodisc membrane protein platform. mGluR3 nanodisc is an optimal solution for screening small molecules targeting mGluR3 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a mGluR3 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.